FDA gives nod to Medtronic's diabetes decision support software

Justine Varieur Cadet | December 13, 2010 | Health Exec | Precision Medicine

The FDA has approved Medtronic’s CareLink Pro 3.0 Therapy Management Software, a software program that offers decision support to healthcare professionals managing diabetes. The company announced a market launch in the U.S.

The software analyzes data from a patient’s insulin pump, continuous glucose monitoring device and blood glucose meter to identify patient information in one dashboard. In addition, the Minneapolis-based Medtronic said it pinpoints the times the patient experienced a hypoglycemic or hyperglycemic glucose pattern and prioritizes these patterns so that clinicians know which times of day are the biggest challenges for their patients.

Justine Varieur Cadet

Around the web

Cardiovascular Business

Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.

AI in Healthcare

A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business

FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

FDA gives nod to Medtronic's diabetes decision support software

Related Content

Around the web